.png)
Séminaire franco –israélien
Thérapies innovantes coûteuses : nos systèmes de santé sont-ils capables de les prendre en charge ?
Les thérapies innovantes (médicaments, dispositifs médicaux, procédures de soins) se présentent sur le marché à des sommes jamais atteintes. On parle de plus de 1 Million d’euros pour certaines thérapies géniques par exemple. Cette tendance ne touche pas uniquement le domaine du médicament, elle concerne également des dispositifs médicaux les prothèses voire des procédures chirurgicales. La capacité des systèmes de soins à prendre en charge ces nouvelles thérapies sans attendre lorsqu’elles répondent à de vraies attentes suppose de trouver des modèles de prise en charge transitoires dans l’attente de la baisse des coûts.
Ce séminaire a pour objectif de faire échanger les points de vue de responsables institutionnels et industriels des deux pays afin de faire émerger des pistes pour le futur.
Tel Aviv University
Sunday, November 5, 2023
8:00 AM - 6 PM
Entrance Gate 4 - After Hall, Naftali building - Faculty of Social Sciences
PROGRAM
8:00 AM
Coffee cakes opening
8:30 AM
Opening Greetings
9:00 AM
Key note address
Dr. Muriel Haim,
president of France-Israel Foundation
Dr Jean-Marc Grognet,
former reserch director CEA
“From small molecules to biologics: 30 years of a continuous increase in drug prices”
Dr. Itay Shurtz
Economist Ben Gurion University
"Healthcare Expenditures: Some Traditional Explanations in an Era of Innovations"
Prof. Avi Domb,
Chief Scientist Ministry for Innovation Science and Technology (MOST)
“Biotech in Israel”
9:40 AM
Health economist's perspective
Prof. Philippe Tibi
Professor of finance,
Ecole polytechnique, Head of the Tech financing task force, French Ministry of Finance
“ Leveraging private financing to achieve public health innovative solutions objectives. Results and Takeaways from France “
Dr. Itay Shurtz
Economist Ben Gurion University
"Healthcare Expenditures: Some Traditional Explanations in an Era of Innovations"
10:20 AM
Coffee Break
11 AM
From Research to the patient
Dr. Frederic Revah
CEO Genethon
“Gene therapy, a revolution at what cost”
Prof. Avi Domb,
Chief Scientist MOST
« Non viral gene therapy »
Prof. Gabriel Malka
Dean Mohamed VI University Marocco
“Biotechnology and new therapies: an approach for emerging countries”
12 AM
From Research to the patient
Moderator: J.M Grognet
Dr. Muriel Dahan,
Director Research and Development Unicancer
“Advancing research to give patients better access to innovation”
Prof. Ronen Loebstein
Director, Institute of Clinical Pharmacology and Toxicology and Drug Management Division, Sheba Medical center
“Towards a data driven learning hospital – The Sheba Medical Center experience”
12:40 AM
Lunch Break
2:10 PM
The regulator's point of view
Moderator: N. Darvish
Dr. Pierre Jean Lancry,
Former Deputy Director of Cnam, in charge of drugs and medical devices
“Are we innovative to finance innovation?”
Prof. D. Ben Yehuda,
Dean Med. School, HUJI Head Oncology dept.
”The assessment and funding processes in rare diseases A rare disease should not receive a rare priority”
3:10 PM
The point of view of the industry and investors
Moderator: P. Tibi
Prof. Nicolas Levy,
Rare diseases director, Servier
Innovative therapies in small populations with high unmet medical: towards a sustainable model?
Nissim Darvish
Managing General Partner at Eliraz Ventures.
“Treatment in face of crisis”
4:10 PM
Coffee Break
4:40 PM
Law and ethics
Moderator: P. Curmi
Sylvain Humbert
Lawyer
“Legal Perspective versus Ethical Approach”
Dr. Sarit Smila Sened
Bob Shapell School of Social Work Tel Aviv University
« Justice and Health Care"
5:20 PM
Final Remarks
Prof. Patrick Curmi
MD, PhD.
Research Director at INSERM,
Evry-Paris Saclay University
Prof. Itai Sened
Dean of the Faculty of Social Sciences Tel Aviv University
6 PM
End of the Workshop
